Although the regional variations in the effect of ticagrelor vs. clopidogrel found in the PLATO trial may have arisen from chance alone, the poor outcomes for North American patients seen with the new ...

Daily aspirin does not reliably prevent bowel cancer in people at average risk, according to a major new review. Any ...

BARCELONA, Spain—(UPDATED) Aspirin has long been the antiplatelet of choice for long-term secondary prevention in patients with coronary disease, but a meta-analysis of several trials suggests P2Y12 ...

Daily aspirin use does not offer a quick or reliable way to prevent bowel cancer in the general population and carries immediate risks of serious bleeding, a new Cochrane review finds.

Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia A total of 23,162 patients ...

A major study involving over 30,000 people across Europe and the U.S. has revealed a surprising link between aspirin use and heart failure risk. Among individuals with at least one risk factor—such as ...

In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to ...

A new meta-analysis of trials evaluating aspirin for primary prevention of cardiovascular disease has found no overall benefit, with aspirin use associated with a lower risk of cardiovascular events ...